Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Braveheart Bio Q3 2026 Results: Net Loss of $26.5M, Loss Narrows

Braveheart Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing its lead candidate BHB-1893 for hypertrophic cardiomyopathy (HCM). The company reports a limited operating history with significant losses and expects to require substantial additional funding to support its ongoing clinical trials, including LIONHEART-HCM and TRUEHEART-HCM.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-26.5-59.1
EPS (diluted, $ a share)$-0.51$-10.05

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: BRVE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Braveheart Bio, Inc.: key numbers

Share price
$18.78Close, Nov 17
Market cap
$1.69B
Shares outstanding
90.04MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Braveheart Bio, Inc.

All →
4:06 PM ET 8-K
Financial Results

Braveheart Bio Financial Results

Braveheart Bio reported third quarter 2026 financial results, ending the period with $503.5 million in cash and investments, providing a runway into 2029. The company highlighted 52-week clinical data for BHB-1893 in obstructive HCM and outlined an updated Phase 3 development strategy designed to simplify dosing and minimize titration.

Term
Q3 2026

“BHB-1893 continues to show a consistent, potentially differentiated profile across multiple clinical studies and our mechanistic work. The 52-week data presented at AHA showed rapid, deep responses that continued to improve over time, including meaningful improvements in pVO2 and KCCQ-CSS, and evidence supporting a highly simplified dosing regimen.”

Travis Murdoch, M.D., President and Chief Executive Officer
3:17 PM ET 8-K
Clinical Trial Data

Braveheart Bio Clinical Trial Data

Braveheart Bio and Hengrui Pharma presented 52-week open-label extension data from a Phase 2 study of HRS/BHB-1893 in obstructive hypertrophic cardiomyopathy (oHCM). The results showed meaningful improvements in exercise capacity (pVO2) and patient-reported outcomes, with 79% of patients achieving a Valsalva LVOT gradient below 30 mmHg at Week 52.

Counterparty
Hengrui Pharma
Term
52 weeks

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.